November 1 at 8:00 a.

In addition, an abstract on ACH-2684 titled HCV NS3 Protease Inhibitor with Powerful Activity against Multiple Genotypes and Known Resistant Variants was previously accepted for poster display. Achillion’s past due breaking poster will become displayed in the Past due Breaking Poster Session on Monday, November 1 at 8:00 a.m. Through the finish of the day’s session. The balance of the business’s posters will be displayed in the HCV Therapy: Preclinical and Early Clinical Advancement Poster Program on Tuesday, 2 at 7:00 a November.m. Through the finish of the day’s program. SOURCE Achillion Pharmaceuticals, Inc.. Abstract on ACH-1625 accepted as late breaking poster presentation at The Liver Meeting 2010 ACH-1625 Protease Inhibitor Abstract Accepted as Late Breaking Poster Growing Data Set Underscores Company’s Significant HCV Franchise Achillion Pharmaceuticals, Inc.WHO: Jane Warner, President and CEO of ALAC Richmond Mayor Gayle McLaughlin Richmond Council Member Tom Butt Public health insurance and housing experts Richmond resident and lung wellness advocate WHERE: Richmond Town Hall 450 Civic Center Plaza Richmond, CA 94804 WHAT: The report cards grades how well each city and county is protecting its occupants against the deadly toll of tobacco. ALAC graded 407 municipalities predicated on local ordinances for smoke-free outdoor air, smoke-free housing and reducing sales of tobacco items.